Songster C L, Barrows G H, Jarrett D D
Cancer. 1980 Mar 15;45(5 Suppl):1099-102. doi: 10.1002/1097-0142(19800315)45:5+<1099::aid-cncr2820451312>3.0.co;2-t.
An immunochemical test for fecal occult blood was developed for use in colon cancer screening. The test employs high titer monospecific antisera to intact human hemoglobin in a radial immunodiffusion assay. Patient smears on specially treated filter paper allow screening procedures similar to those using Hemoccult slides. Minimum detectible hemoglobin was 0.3 mg/gm stool, and no cross reactivity with dietary constituents, drugs, or chemicals occurred. The accession of 150 consecutive cases of colon-rectal carcinoma was accomplished from three community hospitals. In each instance, at least one preoperative fecal specimen was obtained for companion smear testing with immunochemical punch-disc and commercial Hemoccult slides. Twenty-nine percent of the cases were found not to be bleeding by either test. Occult bleeding was detected by Hemoccult in 40% of the cases, and occult bleeding was detected by immunochemical testing in 65% of the cases. A surprising discovery was that rectal lesions had a much lower rate of of positiuity with both tests (Hemoccult-29%, Immunochemical-50%) than other locations. These results suggest that immunochemical screening for occult blood loss will provide a higher rate of detection of colon cancer.
一种用于结肠癌筛查的粪便潜血免疫化学检测方法被开发出来。该检测方法在放射免疫扩散试验中采用高滴度单特异性抗血清来检测完整的人血红蛋白。患者在经过特殊处理的滤纸上涂片,使得筛查程序类似于使用Hemoccult玻片的程序。最低可检测到的血红蛋白量为0.3毫克/克粪便,并且与饮食成分、药物或化学物质没有交叉反应。从三家社区医院收集了连续150例结肠直肠癌病例。在每个病例中,至少获取一份术前粪便标本,用于与免疫化学打孔盘和商用Hemoccult玻片进行配套涂片检测。两种检测方法均发现29%的病例没有出血。Hemoccult检测到40%的病例有潜血,免疫化学检测检测到65%的病例有潜血。一个惊人的发现是,与其他部位相比,直肠病变在两种检测方法中的阳性率都要低得多(Hemoccult为29%,免疫化学检测为50%)。这些结果表明,免疫化学筛查潜血将提供更高的结肠癌检测率。